Drug Trial Radar · NCT06712641
Aminoglycosides in Early Sepsis
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,900
Planned (sponsor's estimate)
Start
Apr 23, 2026
Primary completion
Jun 2028
Study completion May 2033
Sponsor
- Lead sponsor
- University Hospital, AkershusAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ullevaal University Hospital
- First posted
- Dec 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance. In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.
Conditions
- Sepsis
Interventions
Gentamicin + narrow spectrum betalactamDrug
Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
CefotaximeDrug
Empirical therapy for suspected community-acquired sepsis with cefotaxime
Piperacillin-tazobactamDrug
Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30-day mortalityTime frame: Up to 30 days after randomization
- 30-day acute kidney injuryTime frame: Up to 30 days after randomization
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Ålesund Hospital, Helse Møre og Romsdal HF
Ålesund, Norway · Not yet recruiting
Bodø Hospital Nordlandssykehuset HF
Bodø, Norway · Not yet recruiting
Drammen Hospital, Vestre Viken HF
Drammen, Norway · Not yet recruiting
Bærum Hospital, Vestre Viken Hospital Trust
Gjettum, Norway · Not yet recruiting
Østfold Hospital Kalnes HF
Grålum, Norway · Not yet recruiting
Nordmøre and Romsdal Hospital, Helse Møre og Romsdal HF
Hjelset, Norway · Not yet recruiting
Ringerike Hospital, Vestre Viken Hospital Trust
Hønefoss, Norway · Not yet recruiting
Akershus University Hospital
Lørenskog, Norway · Recruiting
Oslo University Hospital Ullevål
Oslo, Norway · Recruiting
Sykehuset Telemark Skien
Skien, Norway · Not yet recruiting
Vestfold Hospital HF
Tønsberg, Norway · Not yet recruiting
University Hospital of North Norway
Tromsø, Norway · Not yet recruiting
Haukeland University Hospital
Bergen, Bergen, Norway · Recruiting
Lovisenberg Diakonal Hospital
Oslo, Oslo, Norway · Recruiting
St. Olav's Hospital
Trondheim, Trondheim, Norway · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.